Abstract
This pathology was first described in 1934 by the Norwegian doctor Asbjorn Fölling, at the Institute of Physiology of the University of Oslo. PKU belongs to the group of hyperphenylalaninemias (HPA), a group that includes the causes that increase the concentration of plasma phenylalanine. The most common cause of HPA is phenylalanine hydroxylase (PAH) deficiency which causes excessive accumulation of phenylalanine in the bloodstream, affecting the central nervous system. Prevention of complications caused by PKU is the main goal at the time of diagnosis. The therapeutic intervention is sustained throughoutlife, this being made up of a diet aimed at limiting the intake of phenylalanine (Cruz et. al., 2002). Several studies have shown a decrease in antioxidant capacity in patients with PKU. Almonds (Prunus dulcis) are an important source of vitamin E (α-tocopherol), a fat-soluble vitamin with an antioxidant role. Brazil nuts (Bertholletia excelsa) are among the richest sources of selenium. The literature describes low selenium levels in patients with PKU. The extraction of α tocopherol and selenium from almond seeds and brazil nuts could contribute to the development of a dietary supplement with antioxidant potential, so that the nutritional status of patients with PKU.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call